Test Directory

Test Code
1564
Test Name
Hyperostosis Corticalis Generalisata, Benign Form Of Worth, With Torus Palatinus
CPT Codes
81406, 81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.

Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours

Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Description

LRP5 related high bone density phenotypes - Hyperostosis corticalis generalisata, benign form of worth, with torus palatinus or endosteal hyperostosis (MIM 144750) is an autosomal dominant disorder caused by mutations in the LDL receptor-related protein 5 (LRP5) gene. The main findings include cortical thickening of the long bones and progressive enlargement of the mandible with decreased gonial angle and the development of torus palatinus. The long bones are not altered in shape but are resistant to fractures. The torus palatinus may lead to malocclusion and tooth loss. The skeleton is usually normal in childhood and the patients are of normal height and proportion. During adolescence the face begins to flatten and the mandibular and palate changes occur. Increased density of the calvarium may be evident on radiographs.

Osteopetrosis, autosomal dominant 1 (OPTA1; MIM 607634) is characterized by diffuse osteosclerosis with pronounced involvement of cranial bones. The cranial vault may be enlarged and a conductive hearing loss may be present. OPTA1 is not associated with an increased fracture rate. OPTA1 is caused by gain of function mutations in the gene encoding the LDL receptor-related protein 5 (LRP5). See also osteopetrosis, autosomal dominant 2 (OPTA2; MIM 166600) caused by mutations in the CLCN7 gene.

Van Buchem disease, type 2 (VBCH2; MIM 607636) is an autosomal dominant, high bone density disorder caused by mutations in the LDL receptor-related protein 5 (LRP5) gene. Clinical features include an enlarged mandible, increased calvarial thickness, cranial osteosclerosis and thickened cortices of long bones. The clinical findings in VBCH2 are similar to those in hyperostosis corticalis generalisata. It has been suggested that these high bone density disorders represent a continuum. The detection of a shared LRP5 mutation in patients with VBCH2 and hyperostosis corticalis generalisata indicates that this is indeed the case. It should be noted that an autosomal recessive variant of Van Buchem disease is recognized. Patients with autosomal recessive Van Buchem disease are more severely affected and present with facial nerve palsies.

Testing Schedule
Monday-Friday
Genes
LRP5
MIM
144750
Disease Group
Metabolic and Endocrine, Skeletal Disorders